NICE plans to use broader range of data in guidance

pharmafile | February 5, 2020 | News story | Research and Development NHS, NHS NICE, NICE 

The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.

NICE approved the plan in principle last month. Health Secretary Matt Hancock said that the agency has a duty to ensure their “rules, processes and ways or working” are up to date.

NICE received 130 comments on its process from clinicians, industry and patient groups. It pledged to make sure it rules and processes are up to date to handle new types of medicines.

This new process will involve making the range of data include patient records, real world evidence from health and social care practice outside of trials, such as registries and clinical audits. This should result in improved guidance and allow existing recommendations to be updated more quickly, said the agency.

NICE intends to provide additional details on its plans in a public board meeting next month.

The plans are intended primarily for the development of guidance aimed at health and social care systems. However there is some overlap with its health technology evaluation methods, which are used to review new therapies for use on the NHS.

Conor Kavanagh


Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine …

Latest content